



Trial Information Summary

ALLG Trial Number:	AML16
Trial Name:	Sorafenib in combination with intensive chemotherapy for previously untreated adult FLT3-ITD positive AML: a Phase 2 randomised double-blind placebo controlled multi-centre study
Lay Summary:	<p>Acute Myeloid Leukaemia (AML) is diagnosed in over 800 Australians each year. Half of these patients are under the age of 65 at the time of diagnosis. Even with intensive chemotherapy and transplantation strategies the 3 year survival rate for these patients is 40%. Most of these patients relapse in the first two years following treatment.</p> <p>The survival of patients with AML where the FLT3 cell mutation is present is poor. The mutation offers resistance of leukaemic cells to treatment, which results in the disease returning.</p> <p>This study will look at how Sorafenib when used with chemotherapy will reduce the effect of this mutation, in adult AML.</p>
Participating Hospitals:	1. Alfred / 2. Austin Health / 3. Box Hill / 4. Calvary Mater Newcastle / 5. Canberra / 6. Concord / 7. Gosford / 8. Nepean / 9. Princess Alexandra / 10. Queen Elizabeth / 11. Royal Adelaide / 12. Royal Brisbane and Women's / 13. Royal Hobart / 14. Royal Melbourne / 15. Royal Prince Alfred / 16. Sir Charles Gairdner / 17. St George / 18. Westmead / 19. Wollongong
Target Accrual (International):	N/A
Target Accrual (ALLG):	99
Expected Final Accrual Date:	December 2018